Healthcare
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Keyword
Lilly
No market stories in the last 7 days. The latest coverage is below.
- 7-day mood
- —Not enough data
- Stories, 7 days
- 0
- Last 24 hours
- 0no baseline yet
- Sources
- 2in the latest 2
Mood and coverage · last 7 days
Market chart- Lilly · 6-hour average
- Hourly reading
- Stories per hour
No scored stories in the last 7 days.
View as table
| Day | Mood | Stories |
|---|---|---|
| Sat, Oct 10 | — | 0 |
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | — | 0 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
| Sat, Oct 3 | — | 0 |
Latest on Lilly
Newest firstHealthcare
Adding Lilly's new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes - much like a GLP-1.
